These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 19229802)

  • 41. Clinical and physiological studies of Raynaud's phenomenon.
    Engelhart M
    Dan Med Bull; 1991 Dec; 38(6):458-68. PubMed ID: 1802635
    [No Abstract]   [Full Text] [Related]  

  • 42. Alpha-adrenergic receptors in platelets from patients with Raynaud's syndrome.
    Keenan EJ; Porter JM
    Surgery; 1983 Aug; 94(2):204-9. PubMed ID: 6308842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Hemodynamic response of the digital artery to heat and cold in normal subjects, in systemic scleroderma and in Raynaud's disease].
    Vayssairat M; Mathieu JF; Housset E
    J Mal Vasc; 1984; 9(1):7-10. PubMed ID: 6707534
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.
    Zamora MR; O'Brien RF; Rutherford RB; Weil JV
    Lancet; 1990 Nov; 336(8724):1144-7. PubMed ID: 1978025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pathogenic role for endothelin in Raynaud's phenomenon?
    Bottomley W; Goodfield M
    Acta Derm Venereol; 1994 Nov; 74(6):433-4. PubMed ID: 7701873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Abnormal amplitude and kinetics of digital postocclusive reactive hyperemia in systemic sclerosis.
    Gaillard-Bigot F; Roustit M; Blaise S; Gabin M; Cracowski C; Seinturier C; Imbert B; Carpentier P; Cracowski JL
    Microvasc Res; 2014 Jul; 94():90-5. PubMed ID: 24990822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of fingertip lacticemy before and after cold stimulus in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Pucinelli ML; Fontenelle S; Andrade LE
    J Rheumatol; 2002 Jul; 29(7):1401-3. PubMed ID: 12136896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infrared-monitored cold response in the assessment of Raynaud's phenomenon.
    Foerster J; Wittstock S; Fleischanderl S; Storch A; Riemekasten G; Hochmuth O; Meffert B; Meffert H; Worm M
    Clin Exp Dermatol; 2006 Jan; 31(1):6-12. PubMed ID: 16309469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis.
    Sulli A; Soldano S; Pizzorni C; Montagna P; Secchi ME; Villaggio B; Seriolo B; Brizzolara R; Cutolo M
    J Rheumatol; 2009 Jun; 36(6):1235-9. PubMed ID: 19369451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the hunting reaction in normals and individuals with Raynaud's disease.
    Jobe JB; Goldman RF; Beetham WP
    Aviat Space Environ Med; 1985 Jun; 56(6):568-71. PubMed ID: 4015569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noninvasive hemodynamic assessment of vasospasm in patients with primary Raynaud's phenomenon.
    van de Wal HJ; Wijn PF; van Lier HJ; Kneepkens WG; Skotnicki SH
    Angiology; 1987 Apr; 38(4):315-32. PubMed ID: 3578920
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Occupational syndromes of the extremities. The role of endothelin in the cold-test vasospasm: a pathogenetic hypothesis].
    Taccola A; Aprile C; Bacchella L
    G Ital Med Lav; 1991; 13(1-6):71-5. PubMed ID: 1845462
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis.
    Lekakis J; Mavrikakis M; Emmanuel M; Prassopoulos V; Papazoglou S; Papamichael C; Moulopoulou D; Kostamis P; Stamatelopoulos S; Moulopoulos S
    Clin Exp Rheumatol; 1998; 16(2):135-40. PubMed ID: 9536388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.